Interleukin-1 and cancer progression: The emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment

Journal of Translational Medicine

Volumn 4, Issue , 2006, Pages

  Lewis, Anne M ^a,b   Varghese, Sheelu ^a,c   Xu, Hui ^a   Alexander, H Richard ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; CELL ADHESION MOLECULE; CYTOKINE; GROWTH FACTOR; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 6; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; PRALNACASAN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VX 765;

ANGIOGENESIS; BREAST CANCER; CANCER GROWTH; CANCER THERAPY; CLINICAL TRIAL; COLON CANCER; CYTOKINE PRODUCTION; DATA ANALYSIS; DRUG HALF LIFE; DRUG TARGETING; GENE EXPRESSION; GENE INDUCTION; HEAD AND NECK CANCER; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATORY CELL; LUNG CANCER; MELANOMA; METASTASIS; NONHUMAN; PHENOTYPE; PROGNOSIS; RECEPTOR BINDING; REVIEW; SOLID TUMOR; STROMA CELL; TUMOR CELL; TUMOR REGRESSION; TUMOR XENOGRAFT; UPREGULATION;

EID: 33845212729     PISSN: 14795876     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-4-48     Document Type: Review

References (46)

1. Kuper H, Adami HO, Trichopoulos D: Infections as a major preventable cause of human cancer. J Intern Med 2000, 248:171-183.
2. Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow? Lancet 2001, 357:539-545.
3. Mantovani A, Muzio M, Garlanda C, Sozzani S, Allavena P: Macrophage control of inflammation: negative pathways of regulation of inflammatory cytokines. Novartis Found Symp 2001, 234:120-31; discussion 131-5.:120-131.
4. Burke F, Relf M, Negus R, Balkwill F: A cytokine profile of normal and malignant ovary. Cytokine 1996, 8:578-585.
5. Komori A, Yatsunami J, Suganuma M, Okabe S, Abe S, Sakai A, Sasaki K, Fujiki H: Tumor necrosis factor acts as a tumor promoter in BALB/3T3 cell transformation. Cancer Res 1993, 53:1982-1985.
6. Apte RN, Krelin Y, Song X, Dotan S, Recih E, Elkabets M, Carmi Y, Dvorkin T, White RM, Gayvoronsky L, Segal S, Voronov E: Effects of micro-environment- and malignant cell-derived interleukin-I in carcinogenesis, tumour invasiveness and tumour-host interactions. Eur J Cancer 2006, 42:751-759.
7. Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, Dinarello CA, Apte RN: IL-I is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A 2003, 100:2645-2650.
8. Dinarello CA: Interleukin-I and interleukin-I antagonism. Blood 1991, 77:1627-1652.
9. Dinarello CA: Biologic basis for interleukin-I in disease. Blood 1996, 87:2095-2147.
10. Endres S, Cannon JG, Ghorbani R, Dempsey RA, Sisson SD, Lonnemann G, Van der Meer JW, Wolff SM, Dinarello, CA: In vitro production of IL 1 beta, IL 1 alpha, TNF and IL2 in healthy subjects: distribution, effect of cyclooxygenase inhibition and evidence of independent gene regulation. Eur J Immunol 1989, 19:2327-2333.
11. Cullinan EB, Kwee L, Nunes P, Shuster DJ, Ju G, McIntyre KW, Chizzonite RA, Labow MA: IL-1 receptor accessory protein is an essential component of the IL-1 receptor. J Immunol 1998, 161:5614-5620.
12. Mantovani A, Locati M, Vecchi A, Sozzani S, Allavena P: Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol 2001, 22:328-336.
13. Dinarello CA, Wolff SM: The role of interleukin-1 in disease. N Engl J Med 1993, 328:106-113.
14. Portier M, Zhang XG, Ursule E, Lees D, Jourdan M, Bataille R, Klein B: Cytokine gene expression in human multiple myeloma. Br J Haematol 1993, 85:514-520.
15. Elaraj DM, Weinreich DM, Varghese S, Puhlmann M, Hewitt SM, Carroll NM, Feldman ED, Turner EM, Alexander HR: The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clin Cancer Res 2006, 12:1088-1096.
16. Chen Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DC, Smith CW, Enamorado I, Yeh NT, Kroog GS, Rudy S, McCullagh L, Mousa S, Quezado M, Herscher LL, Van Waes C: Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 1999, 5:1369-1379.
17. Gemma A, Takenaka K, Hosoya Y, Matuda K, Seike M, Kurimoto F, Ono Y, Uematsu K, Takeda Y, Hibino S, Yoshimura A, Shibuya M, Kudoh S: Altered expression of several genes in highly metastatic subpopulations of a human pulmonary adenocarcinoma cell line. Eur J Cancer 2001, 37:1554-1561.
18. Apte RN, Voronov E: Interleukin-I - a major pleiotropic cytokine in tumor-host interactions. Semin Cancer Biol 2002, 12:277-290.
19. Konishi N, Miki C, Yoshida T, Tanaka K, Toiyama Y, Kusunoki M: Interleukin-1 receptor antagonist inhibits the expression of vascular endothelial growth factor in colorectal carcinoma. Oncology 2005, 68:138-145.
20. Barille S, Akhoundi C, Collette M, Mellerin MP, Rapp MJ, Harousseau JL, Bataille R, Amiot M: Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-I by myeloma cells. Blood 1997 90:1649-1655.
21. Akagi Y, Liu W, Xie K, Zebrowski B, Shaheen RM, Ellis LM: Regulation of vascular endothelial growth factor expression in human colon cancer by interleukin-1 beta. Br J Cancer 1999, 80:1506-1511.
22. Sawai H, Funahashi H, Yamamoto M, Okada Y, Hayakawa T, Tanaka M, Takeyama H, Manabe T: Interleukin-1 alpha enhances integrin alpha(6)beta(1) expression and metastatic capability of human pancreatic cancer. Oncology 2003, 65:167-173.
23. Nozaki S, Sledge GWJ, Nakshatri H: Cancer cell-derived interleukin 1 alpha contributes to autocrine and paracrine induction of pro-metastatic genes in breast cancer. Biochem Biophys Res Commun 2000, 275:60-62.
24. Saijo Y, Tanaka M, Miki M, Usui K, Suzuki T, Maemondo M, Hong X, Tazawa R, Kikuchi T, Matsushima K, Nukiwa T: Proinflammatory cytoldne IL-1 beta promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interaction. J Immunol 2002, 169:469-475.
25. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC: Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990, 348:550-552.
26. Cominelli F, Nast CC, Clark BD, Schindler R, Lierena R, Eysselein VE, Thompson RC, Dinarello CA: Interleukin-1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest 1990, 86:972-980.
27. Rambaldi A, Torcia M, Bettoni S, Vannier E, Barbui T, Shaw AR, Dinarello CA, Cozzolino F: Modulation of cell proliferation and cytokine production in acute myeloblastic leukemia by interleukin-1 receptor antagonist and lack of its expression by leukemic cells. Blood 1991, 78:3248-3253.
28. Weinreich DM, Elaraj DM, Puhlmann M, Hewitt SM, Carroll NM, Feldman ED, Turner EM, Spiess PJ, Alexander HP: Effect of Interleukin 1 Receptor Antagonist Gene Transduction on Human Melanoma Xenognafts in Nude Mice. Cancer Res 2003, 63:5957-5961.
29. Schraufstatter IU, Chung J, Burger M: IL-8 activates endothelial cell CXCR1 and CXCR2 through Rho and Rac signaling pathways. Am J Physiol Lung Cell Mol Physiol 2001, 280:L1094-L1103.
30. Neidhart M, Gay RE, Gay S: Anti-interleukin-1 and anti-CD44 interventions producing significant inhibition of cartilage destruction in an in vitro model of cartilage invasion by rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2000, 43:1719-1728.
31. Braddock M, Quinn A: Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat Rey Drug Discov 2004, 3:330-339.
32. Eastgate JA, Symons JA, Duff GW: identification of an interleukin-1 beta binding protein in human plasma. FEBS Lett 1990, 260:213-216.
33. Symons JA, Eastgate JA, Duff GW: A soluble binding protein specific for interleukin 1 beta is produced by activated mononuclear cells. Cytokine 1990, 2:190-198.
34. Jouvenne P, Vannier E, Dinarello CA, Miossec P: Elevated levels of soluble interleukin-1 receptor type II and interieukin-1 receptor antagonist in patients with chronic arthritis: correlations with markers of inflammation and joint destruction. Arthritis Rheum 1998, 41:1083-1089.
35. Re F, Sironi M, Muzio M, Matteucci C, Introna M, Orlando S, Penton-Rol G, Dower SK, Sims JE, Colotta F, Mantovani A: Inhibition of interleukin-1 responsiveness by type II receptor gene transfer: a surface "receptor" with anti-interleukin-1 function. J Exp Med 1996, 183:1841-1850.
36. Bossu P, Visconti U, Ruggiero P, Macchia G, Muda M, Bertini R, Bizzarri C, Colagrande A, Sabbatini V, Maurizi G,.: Transfected type II interleukin-1 receptor impairs responsiveness of human keratinocytes to interleukin-1. Am J Pathol 1995, 147:1852-1861.
37. Bessis N, Guery L, Mantovani A, Vecchi A, Sims JE, Fradelizi D, Boissier MC: The type II decoy receptor of IL-1 inhibits murine collagen-induced arthritis. Eur J Immunol 2000, 30:867-875.
38. Smith DE, Hanna R, Della F, Moore H, Chen H, Farese AM, MacVittie TJ, Virca GD, Sims JE: The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity 2003, 18:87-96.
39. Symons JA, Young PR, Duff GW: Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist. Proc Natl Acad Sci USA 1995, 92:1714-1718.
40. Burger D, Chicheportiche R, Giri JG, Dayer JM: The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor. J Clin Invest 1995, 96:38-41.
41. Naik SM, Cannon G, Burbach GJ, Singh SR, Swerlick RA, Wilcox JN, Ansel JC, Caughman SW: Human keratinocytes constitutively express interleukin-18 and secrete biologically active interleukin-18 after treatment with pro-inflammatory mediators and dinitrochlorobenzene. J Invest Dermatol 1999, 113:766-772.
42. Randle JC, Harding MW, Ku G, Schonharting M, Kurrle R: ICE/Caspase-1 inhibitors as novel anti-inflammatory drugs. Expert Opin Investig Drugs 2001, 10:1207-1209.
43. Kuida K, Lippke JA, Ku G, Harding MW, Livingston DJ, Su MS, Flavell RA: Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science 1995, 267:2000-2003.
44. Li P, Allen H, Banerjee S, Franklin S, Herzog L, Johnston C, McDowell J, Paskind M, Rodman L, Salfeld J,.: Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock. Cell 1995, 80:401-411.
45. Rudolphi K, Gerwin N, Verzijl N, van der KP, van den BW: Pralnacasan, an inhibitor of interleuldn-1 beta converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthritis Cartilage 2003, 11:738-746.
46. Economides AN, Carpenter LR, Rudge JS, Wong V, Koehler-Stec EM, Hartnett C, Pyles EA, Xu X, Daly TJ, Young MR, Fandl JP, Lee F, Carver S, McNay J, Bailey K, Ramakanth S, Hutabarat R, Huang TT, Radziejewski C, Yancopoulos GD, Stahl N: Cytokine traps: multicomponent, high-affinity blockers of cytokine action. Nat Med 2003, 9:47-52.